Form 4: Iteos Therapeutics Director, Jill DeSimone, Acquires Stock Options
SEC Form 4
Director Jill DeSimone acquired 44,766 stock options in Iteos Therapeutics, Inc. on March 7, 2024.
Summary
- On March 7, 2024, Jill DeSimone, a director of iTeos Therapeutics, Inc., acquired 44,766 stock options.
- The exercise price of these options is $11.58.
- The options vest over three years, with one-third vesting on March 7, 2025, and the remainder vesting in equal monthly installments over the subsequent 24 months, contingent upon continued service as a director.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, which is a neutral event.
Industry Context
This is a standard practice for compensating and incentivizing board members in publicly traded companies, aligning their interests with those of the shareholders.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of transaction: Jill DeSimone acquired stock options. |
| 03/07/2025 | First vesting date: 1/3 of the stock options vest. |
| 03/07/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.